Roche announces data from Phase 3 Portal study of Susvimo

Genentech, a member of the Roche (RHHBY) Group, announced new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo for the treatment of people with wet AMD. Results show that Susvimo’s immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists 2025 Annual Meeting in Long Beach, California. “These long-term results reinforce Susvimo’s ability to maintain vision and retinal drying over a long period of time for people with wet AMD, the leading cause of vision loss in people over age 60. These robust data reinforce our confidence in Susvimo’s unique therapeutic approach, providing an effective alternative to regular eye injections while preserving vision in a sustained manner,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development.